LDE225 is primarily used in the treatment of basal cell carcinoma, a common type of skin cancer. It works by inhibiting the Hedgehog signaling pathway, which is often abnormally activated in this cancer. This targeted therapy helps to reduce tumor growth and can be effective in cases where surgery or radiation is not suitable. Additionally, it is being investigated for potential use in other cancers where the Hedgehog pathway plays a significant role, such as medulloblastoma and certain types of advanced solid tumors. Its application offers a promising approach for patients with limited treatment options.